SciSparc Ltd. is a clinical stage pharmaceutical company, which focuses on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. The firm initiated two internal drug development programs based on repurposing an FDA approved synthetic cannabinoid (dronabinol): Joint Pharma developing THX-TS01 targeted to the treatment of TS and Brain Bright Pharma developing THX-ULD01 targeted to the high value and under-served market of MCIs. Its products include SCI-110, SCI-210, SCI-160, and CannAmide. The company was founded on August 23, 2004 and is headquartered in Tel Aviv, Israel.
相关临床试验
5
2 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
2014
进行中（未招募）
1
20.0%
尚未招募
1
20.0%
招募中
1
20.0%
Unknown
2
40.0%
暂无批准数据
- NeuroThera Labs has launched a Phase IIb clinical trial site at Hannover Medical School in Germany for SCI-110, its cannabinoid-based treatment candidate for adult Tourette Syndrome. - The randomized, double-blind, placebo-controlled, cross-over trial will also enroll patients at Yale Child Study Center and Tel Aviv Sourasky Medical Center. - SCI-110 combines dronabinol with palmitoylethanolamide and previously demonstrated a 21% average tic reduction in the Phase IIa study as measured by the Yale Global Tic Severity Scale. - The primary efficacy endpoint is change in tic severity at weeks 12 and 26 compared to baseline, with safety assessed through adverse event monitoring.
- NeuroThera Labs, a SciSparc subsidiary focused on CNS disorders, signed a definitive agreement to acquire 54.01% of CliniQuantum for approximately $9.46 million in stock consideration. - CliniQuantum develops quantum computing platforms to transform clinical trials by analyzing complex datasets for smarter, faster, and more adaptive study designs. - The acquisition includes potential earn-out payments up to $2.5 million based on patent filings and fundraising milestones over a three-year period. - The transaction is expected to close around March 31, 2026, pending Israeli tax authority approval and other closing conditions.
- NeuroThera Labs has received a U.S. patent for its proprietary combination of antimicrobials and cannabinoids, including THC and CBD, designed to enhance existing antibiotics against resistant bacterial strains. - The patented technology demonstrated in preclinical studies the ability to restore effectiveness of antibiotics against methicillin-resistant Staphylococcus aureus (MRSA), which caused approximately 130,000 deaths worldwide in 2021. - The platform combines decades-old antibiotics with cannabinoids to potentially eliminate the need for constant development of new antibiotics while leveraging proven safety profiles. - This patent strengthens global intellectual property protection alongside previously granted patents in the U.S. and Europe for the antimicrobial-potentiating platform.
- NeuroThera Labs Inc., a clinical-stage pharmaceutical company developing CNS disorder treatments, has signed a non-binding term sheet to acquire a 55% stake in an Israeli quantum computing bio data analysis company. - The acquisition aims to leverage quantum computing principles including superposition, entanglement, and parallelism to revolutionize clinical data analysis and accelerate medical research and development. - NeuroThera currently develops cannabinoid-based therapeutics including SCI-110 for Tourette syndrome and Alzheimer's disease, and SCI-210 for autism spectrum disorder and status epilepticus. - The transaction remains subject to due diligence, definitive agreements, and regulatory approvals, with no guarantee of completion.
- SciSparc Ltd. signed a definitive agreement to acquire a comprehensive patent portfolio for endoscopic technologies from Xylo Technologies, including the MUSE single-use endoscopic system for treating gastroesophageal reflux disease. - The acquisition will be completed through issuing ordinary shares representing 19.99% of SciSparc's outstanding capital, with closing expected by March 8, 2026, subject to regulatory approvals. - The company plans to commercialize the MUSE system globally through exclusive regional partnerships in North America, Europe, and Latin America, targeting the $2.5 billion GERD device market projected to reach $3.03 billion by 2030.
- SciSparc Ltd. signed a binding term sheet to acquire patents for the MUSE™ endoscopic system from Xylo Technologies, targeting gastroesophageal reflux disease treatment. - The MUSE™ system is a single-use endoscopic device designed for transoral fundoplication, a minimally invasive procedure to treat GERD. - SciSparc plans to replicate Xylo's successful Greater China commercialization model across North America, Europe, and Latin America through exclusive partnerships. - The global GERD device market was valued at $2.5 billion in 2024 and is projected to reach $3.03 billion by 2030, growing at a 3.24% CAGR.
- SciSparc entered a definitive agreement to transfer its advanced clinical-stage pharmaceutical portfolio valued at $11.6 million to Miza III Ventures Inc., a publicly traded Canadian company. - The transaction will give SciSparc a controlling 75-84% stake in Miza, which will be renamed NeuroThera Labs Inc. and focus on pharmaceutical and supplemental sectors. - SciSparc's transferred portfolio includes SCI-110 for Tourette syndrome (Phase IIb trial), SCI-110 for Alzheimer's disease (completed Phase II), and SCI-210 for autism (ongoing randomized controlled trial). - The deal includes additional financing commitments of up to CAD $1 million through a convertible note and 4 million payment warrants, with closing expected around October 22, 2025.
- N2OFF stockholders approved the acquisition of MitoCareX Bio, a biotech company developing novel therapies for hard-to-treat cancers by targeting the mitochondrial SLC25 protein family. - MitoCareX utilizes 3D comparative modeling and advanced in-vitro screening systems to identify anti-cancer small molecule therapeutics through its computational platform. - The transaction involves N2OFF purchasing shares for $700,000 and exchanging additional shares totaling 40% of the company's fully diluted capital stock, with closing expected in the first half of October 2025. - The global cancer therapeutics and biotherapeutics market was valued at $194.1 billion in 2024 and is projected to reach $344.1 billion by 2031.
- SciSparc Ltd. announced its board of directors resolved to launch an innovative quantum computing-enabled 3D protein modeling initiative aimed at transforming AI drug discovery. - The initiative leverages quantum computing technology to achieve unprecedented accuracy in predicting protein structures and interactions with ligands, potentially advancing structural biology and personalized medicine. - The company will form a dedicated research team and collaborate with quantum computing and structural biology experts, focusing initially on neurological and rare diseases. - SciSparc plans to incorporate a new wholly owned Israeli subsidiary to operate the initiative and create new intellectual property in quantum-enabled drug discovery tools.
- DelveInsight reports over 50 pharmaceutical companies are actively developing 55+ cannabinoid therapies across various clinical stages, representing significant momentum in the therapeutic cannabis space. - Recent clinical milestones include positive Phase II results for IGC-AD1 in Alzheimer's agitation, FDA orphan drug designation for BRC-002 in complex regional pain syndrome, and successful Phase I completion for OCT461201. - Leading pipeline candidates target diverse conditions including neurodegenerative diseases, chronic pain, epilepsy, and inflammatory disorders, with multiple drugs advancing through Phase II and Phase III trials. - The expanding pipeline reflects growing clinical validation for cannabinoids in treating conditions like Alzheimer's disease, chronic pain, and rare epilepsy syndromes, supported by increasing medical cannabis legalization.
